Beside p.T790MEGFR and MUTKRAS, other mechanisms of acquired resistance not evaluated in our study have been described in tumor re-biopsies after EGFR-TKI progression, including actionable mutations of MET [7], HER2 [8], PIK3CA [9] or transformation into small cell histology (3%) [11]. This evidence concerns the gene EGFR and neoplasm.